论文部分内容阅读
目的观察全身化疗联用腹腔内化疗对II~III期胃癌患者的疗效是否优于单用全身化疗。方法2000年1月至12月,58例II~III期胃癌根治术后患者被随机分到不同治疗组(全身化疗联用腹腔内化疗作为研究组,单用全身化疗为对照组),并作随访观察。结果三年以后,研究组的复发率(17.2%)低于对照组(44.4%),而研究组的生存率(86.2%)明显高于对照组(59.3%),两组在复发率和生存率上均有明显的统计学差异(P<0.05),而两组的毒副反应无明显的统计学差异(P>0.05)。结论全身化疗联用腹腔内化疗对II~III期胃癌根治性术后患者的疗效优于单用全身化疗,而毒副反应并无明显增加。
Objective To observe whether systemic chemotherapy plus intraperitoneal chemotherapy is superior to systemic chemotherapy in patients with stage II-III gastric cancer. Methods From January 2000 to December 2000, 58 patients with stage II-III gastric cancer were randomly divided into different treatment groups (systemic chemotherapy plus intraperitoneal chemotherapy as study group and systemic chemotherapy alone as control group) Follow-up observation. Results Three years later, the recurrence rate of the study group (17.2%) was lower than that of the control group (44.4%), while the survival rate of the study group (86.2%) was significantly higher than that of the control group (59.3% (P <0.05). There was no significant difference between the two groups in the side effects (P> 0.05). Conclusions Systemic chemotherapy combined with intraperitoneal chemotherapy is superior to systemic chemotherapy in patients with stage II-III gastric cancer after curative surgery, but no obvious increase in toxic and side effects.